Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”

Oct 03 2018

• By Joseph Haas

Related Content

Novartis Aims To Leap-Frog Into Next Immuno-Oncology Wave With Aduro

Apr 01 2015

Janssen signs $847m lung cancer immunotherapy deal with Aduro

Oct 20 2014

Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

Feb 10 2017

Related Companies

Aduro Biotech, Inc.

Johnson & Johnson

Johnson & Johnson

Novartis AG

Bristol Myers Squibb Company

Momenta Pharmaceuticals, Inc.

Neon Therapeutics, Inc.

BioNTech SE

Stanford University

Additional Topics

Commercial Deals Business Strategies Cancer BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.